ORCA
Online Research @ Cardiff
Browse by Current Cardiff authors
![[up]](/style/images/multi_up.png)
Up a levelNumber of items: 9.
Halilovic, Melisa, Abdelsalam, Mohamed, Zabkiewicz, Joanna  ORCID: https://orcid.org/0000-0003-0951-3825, Lazenby, Michelle, Alvares, Caroline ORCID: https://orcid.org/0000-0003-4391-9802, Schmidt, Matthias, Brenner, Walburgis, Najafi, Sara, Oehme, Ina, Hieber, Christoph, Zeyn, Yanira, Bros, Matthias, Sippl, Wolfgang and Krämer, Oliver H.
2024.
Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.
Leukemia
38
, pp. 2561-2572.
10.1038/s41375-024-02405-5
|
|
|
Zabkiewicz, Joanna ORCID: https://orcid.org/0000-0003-0951-3825, Lazenby, Michelle, Edwards, Gareth, Bygrave, Ceri A., Omidvar, Nader, Zhuang, Lihui, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441, Guy, Carol, Hills, Robert K. ORCID: https://orcid.org/0000-0003-0166-0062, Burnett, Alan K. and Alvares, Caroline L. ORCID: https://orcid.org/0000-0003-4391-9802
2020.
Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia.
British Journal of Haematology
191
(2)
, pp. 231-242.
10.1111/bjh.16665
|
|
|
Lazenby, Michelle
2019.
Characterisation of extracellular vesicles from the microenvironment in high risk acute myeloid leukaemia.
MPhil Thesis,
Cardiff University.
Item availability restricted. |
|
|
|
Ostronoff, F., Othus, M., Lazenby, Michelle, Estey, E., Appelbaum, F. R., Evans, Anna ORCID: https://orcid.org/0000-0002-2430-811X, Godwin, J., Gilkes, Amanda F., Kopecky, K. J., Burnett, Alan, List, A. F., Fang, M., Oehler, V. G., Petersdorf, S. H., Pogosova-Agadjanyan, E. L., Radich, J. P., Willman, C. L., Meshinchi, S. and Stirewalt, D. L.
2015.
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council report.
Journal of Clinical Oncology
33
(10)
, pp. 1157-1164.
10.1200/JCO.2014.58.0571
|
|
|
Lazenby, Michelle, Gilkes, Amanda, Marrin, C., Evans, Anna ORCID: https://orcid.org/0000-0002-2430-811X, Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062 and Burnett, A. K.
2014.
The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial.
Leukemia
28
, pp. 1953-1959.
10.1038/leu.2014.90
|
|
|
|
Walsby, Elisabeth Jane ORCID: https://orcid.org/0000-0001-8523-5017, Lazenby, Michelle, Pepper, Christopher John, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441 and Burnett, Alan Kenneth
2013.
The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
British Journal of Haematology
161
(1)
, pp. 57-67.
10.1111/bjh.12215
|
|
|
|
Walsby, Elisabeth Jane ORCID: https://orcid.org/0000-0001-8523-5017, Lazenby, Michelle, Pepper, Christopher John and Burnett, Alan Kenneth
2011.
The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.
Leukemia
25
(3)
, pp. 411-419.
10.1038/leu.2010.290
|
|
|
|
Gale, Rosemary, Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Green, Claire, Patel, Yashma, Gilkes, Amanda F., Lazenby, Michelle, Wheatley, Keith, Linch, David C. and Burnett, Alan Kenneth
2008.
The impact of FLT3-ITD and NPM1 Mutational Status on the outcome of ATRA therapy in patients with Non-APL AML: results of the UK MRC AML12 trial [Abstract].
Blood -New York-
112
(11)
, p. 207.
|
|
|